Peter Thiel and Jeff Bezos are backing a health care company that aims to change cancer treatment by targeting tumors with sound waves https://t.co/ukDVXsaMQ9 ...

Core Insights - Taiho Oncology Inc. and Cullinan Therapeutics Inc. presented new data from the CNS involvement cohort of the REZILIENT2 study for zipalertinib in advanced or metastatic NSCLC with specific EGFR mutations, to be showcased at ESMO Congress 2025 [1] Summary of Preliminary Efficacy - The ongoing Phase 2b REZILIENT2 trial includes a CNS involvement cohort where 32 patients received zipalertinib 100 mg orally twice daily, with a median of 2 prior lines of therapy [3] - Among the enrolled patients, 21 had ex20ins mutations and 13 had other uncommon mutations [3] - In the evaluable population (n=16), the intracranial objective response rate was 31.3%, with one complete response, and the intracranial disease control rate was 68.8% [4] - The median intracranial duration of response was 8.1 months [4] - The preliminary systemic objective response rate was 27.6% with a median duration of response of 7.6 months [5] - Intracranial antitumor activity was comparable to overall systemic anticancer activity [5] Summary of Preliminary Safety and Tolerability - Zipalertinib was well tolerated at the administered dose, with no new safety signals reported [6] - Treatment-related adverse events of grade 3 or higher occurred in 25% of patients, including anemia and interstitial lung disease, with one death attributed to interstitial lung disease [6] - Following the data release, CGEM stock increased by 4.96% to $7.77 [6]

Core Insights - Nurix Therapeutics is focused on developing innovative therapies for cancer treatment, particularly its oral BTK degrader, bexobrutideg, targeting chronic lymphocytic leukemia (CLL) [1][5] - The company plans to initiate a pivotal phase 2 study in late 2025, indicating a strong commitment to advancing its clinical programs [1][5] Financial Summary - Stifel Nicolaus has set a price target of $33 for NRIX, suggesting a potential upside of approximately 238% from its current price of $9.76 [2][5] - The stock has experienced a decrease of 10.13%, reflecting market volatility, while the company's market capitalization stands at $750.3 million [2] Clinical Data - Nurix's phase 1a data for bexobrutideg shows an impressive 80.9% overall response rate (ORR), supporting the potential for Accelerated Approval [3][5] - The company aims to expand its efforts with a phase 3 trial and explore combination therapies for CLL, targeting a multibillion-dollar market [3][5] Stock Performance - The stock has fluctuated between $9.50 and $10.56 today, with a 52-week high of $29.56 and a low of $8.18, indicating active investor interest [4] - Trading volume stands at 1,996,408 shares, suggesting significant market activity [4]

Core Insights - Aethlon Medical, Inc. has provided updates on its ongoing oncology clinical trial in Australia, focusing on the Hemopurifier's effects on cancer patients not responding to anti-PD-1 therapy [3][4][11] Clinical Trial Observations - The initial cohort of three patients showed promising changes in extracellular vesicles (EVs), microRNAs, and lymphocyte counts after a single treatment with the Hemopurifier [4][5] - Changes in EV and microRNA levels typically returned to baseline within 1 to 3 weeks post-treatment [6] - Two of the three participants exhibited decreases in large EVs, which are implicated in cancer metastasis and immune response inhibition [10] Hemopurifier Mechanism - The Hemopurifier is designed to remove enveloped viruses and tumor-derived EVs from circulation, potentially aiding in cancer treatment by targeting mannose-rich surfaces on EVs and viral proteins [9][11] - The device has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [11] Patient Response and Data Limitations - Increases in total T cell numbers and specific T cell subsets were noted in participants following treatment, although the data is limited due to the small sample size [10] - The study's preliminary nature means that no definitive conclusions can be drawn regarding the clinical efficacy of the Hemopurifier [8][10]

Core Insights - Aethlon Medical, Inc. is conducting an ongoing oncology clinical trial in Australia to evaluate the safety, feasibility, and dose-finding of its Hemopurifier device in cancer patients unresponsive to anti-PD-1 therapy [1][2] Summary by Categories Clinical Trial Observations - Preliminary results from the first patient cohort indicate encouraging changes in extracellular vesicles (EVs), microRNAs, and lymphocyte counts after a single Hemopurifier treatment [2][3] - In the initial three patients, two showed decreases in large EVs, which are implicated in cancer metastasis and immune evasion [7] - All three participants exhibited decreases in large EVs carrying PD-L1, which is associated with resistance to anti-PD-1 therapies [7] - Seven out of ten microRNAs examined showed decreases in two of the three participants following treatment, indicating potential effects on cancer growth and metastasis [7] - Improvements in laboratory ratios related to immunotherapy responses were observed in at least two participants after treatment [7] Device Information - The Aethlon Hemopurifier® is designed to remove enveloped viruses and tumor-derived EVs from circulation, potentially aiding in cancer treatment [9] - The device operates extracorporeally and utilizes a combination of plasma separation, size exclusion, and affinity binding [9] - It holds a U.S. Food and Drug Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [10] Limitations and Future Directions - The small sample size limits the ability to draw definitive conclusions about the efficacy and dose response of the Hemopurifier [3][8] - Further data from subsequent cohorts will be necessary to determine the reproducibility of the observed changes and the potential for dose-dependent effects [3] - The current observations are part of an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters [8]

Core Insights - Rigel Pharmaceuticals (RIGL) is advancing its hematology and oncology pipeline, with Tavalisse being the primary revenue driver [1][2] Product Performance - Tavalisse, an oral spleen tyrosine kinase inhibitor, generated sales of $68.5 million in the first half of 2025, reflecting a 44% year-over-year increase [2][10] - Rezlidhia, the second FDA-approved product, reported sales of $13.1 million in the same period, up 31% year over year [3][10] - Gavreto was added to Rigel's portfolio in 2024, contributing incremental sales starting June 2024, which positively impacted the company's revenue in the first half of 2025 [5][10] Future Outlook - Rigel expects steady sales growth as it expands its commercial presence and enhances marketing efforts, projecting total revenues of $270-$280 million for 2025, up from a previous estimate of $200-$210 million [6] Pipeline Development - Rigel is conducting a phase Ib study for R289, a dual IRAK1 and IRAK4 inhibitor, in patients with lower-risk myelodysplastic syndrome (MDS), with plans to initiate the dose expansion phase in the second half of 2025 [8] - The company is also exploring Rezlidhia's application in other cancers with IDH1 mutations, which could serve as a significant growth catalyst [9] Competitive Landscape - The recent FDA approval of Sanofi's Wayrilz (rilzabrutinib) for chronic ITP poses a competitive threat to Tavalisse, despite differing mechanisms of action [11] - Other companies are also developing treatments that may compete with Rigel's marketed products, including Eli Lilly's Retevmo (selpercatinib) for cancer indications [12] Stock Performance and Valuation - Rigel's shares have increased by 70.2% year to date, outperforming the industry and the S&P 500 [13] - The company is trading at a price-to-sales (P/S) ratio of 1.94, below the industry average of 2.47 and its five-year mean of 2.21 [14] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen from $2.68 to $5.10 over the past 60 days, with 2026 EPS estimates increasing from $1.61 to $3.07 [17]

Genmab to Buy Cancer-Treatment Developer Merus For $8 Bln in Cash https://t.co/SOvnBOpIrE ...

Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it. https://t.co/p6z3ajkmUw ...

[Music] I thank the organizers for this beautiful wonderful program. Uh thank you so much uh director sir and his team. Um my father Shri Babradesh pan uh he was a freedom fighter.He lived more than 100 years and uh father had very beautiful connections. So I have utilized maximum uh with that I'm here with you all today. Connections are very very important in life.uh he was well connected with politicians and the business people all the social workers in Kaluri. Uh my mother Shrimati Ratama she sold the ve ...

Core Insights - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, and its CEO has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London [1][2] Company Overview - Allarity Therapeutics is dedicated to developing personalized cancer treatments, particularly stenoparib for advanced ovarian cancer patients, utilizing its Drug Response Predictor (DRP) technology [5] - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [3] Drug Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential therapeutic action against various cancers, including ovarian cancer [3] - The DRP companion diagnostic platform is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [4] Conference Participation - CEO Thomas Jensen will present a talk titled "A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib" at the conference on October 1, 2025, and will be available for individual meetings to discuss business development opportunities [6][8]